Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Exclusive Interview With CytRx Corp. (CYTR) Company Leaders Released By MissionIR

|Includes: CytRx Corporation (CYTR)

A recent exclusive interview with CytRx Corp. President and CEO Steven Kriegsman, along with company Vice President of Business Development and Investor Relations David Haen, is accessible online in its entirety. The interview discusses various details about CytRx, including its product pipeline, business model, 2013 accomplishments and important new developments.

CytRx is a biopharmaceutical research and development company engaged in the development of cancer drugs for various indications. The company's primary focus is on its proprietary delivery technology for potent oncology therapies.

Among subjects discussed in the interview is CytRx's lead candidate, aldoxorubicin, which is an improved version of doxorubicin, the widely used chemotherapy agent. Among aldoxorubicin's attributes thus far in clinical studies and trials, the agent has shown a reduction in adverse events for patients when contrasted with doxorubicin, as well as improved efficacy and the ability to reach tumors more quickly. CytRx holds the exclusive global rights to aldoxorubicin.

Phase 2b results for aldoxorubicin are expected in December of this year, and a pivotal Phase III trial with a special protocol assessment is scheduled to commence in the first quarter of 2014.

Details about CytRx's pipeline are further discussed in the interview. Additionally, Kriegsman and Haen talk about their own backgrounds and industry experience and detail the rest of the company's management team, as well. Concluding the interview, Kriegsman discusses the company's achievements in 2013 and offers insight regarding recent company news and important forthcoming developments.

The full audio interview can be accessed at For more information about CytRx, visit the company's website at

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit